<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1984">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351191</url>
  </required_header>
  <id_info>
    <org_study_id>NBC-COVID1902</org_study_id>
    <nct_id>NCT04351191</nct_id>
  </id_info>
  <brief_title>PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds</brief_title>
  <acronym>PRECISE</acronym>
  <official_title>Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Government of Punjab, Specialized Healthcare and Medical Education Department</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Hospital Lahore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Services Hospital, Lahore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pakistan Kidney and Liver Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Government of Punjab, Specialized Healthcare and Medical Education Department</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with
      an intent to reduce burden on institutional healthcare services by determining efficacy of
      different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2
      infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective double blind randomized superiority clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RT-PCR result</measure>
    <time_frame>6th and 7th day</time_frame>
    <description>Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of symptoms</measure>
    <time_frame>7 days</time_frame>
    <description>Time to progression to next stage of SARS-CoV-2 disease severity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Sars-CoV2</condition>
  <condition>Symptomatic Condition</condition>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>HCQ Regular dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCQ Loading dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CQ regular dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cholorquine 500 mg BID for 5 days plus standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine Sulfate Regular dose</intervention_name>
    <description>Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2</description>
    <arm_group_label>HCQ Regular dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine Sulfate Loading Dose</intervention_name>
    <description>Hydroxychloroquine administered as a loading dose only</description>
    <arm_group_label>HCQ Loading dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2</description>
    <arm_group_label>CQ regular dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Standard of Care plus placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptomatic patients: defined as fever (temperature greater than 100 degree F), cough,
             or shortness of breath (respiratory rate &gt;22 per minute).

          2. Nasopharyngeal RT-PCR positive SARS-CoV-2

          3. Age 20-50 years

          4. BMI 18-28 kg/m2

          5. Informed consent

        Exclusion Criteria:

          1. O2 saturation by pulse-oximeter below 93%

          2. Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes

          3. Arrhythmias and/or history of arrythmia

          4. Psoriasis and/or history of psoriasis

          5. Neuropathy or myopathy and/or history of these

          6. Hypoglycemia and/or history of hypoglycemia

          7. Pre-existing hepatic disease

          8. Pre-existing renal disease

          9. Use of antacids within 1 week

         10. Use of antiobiotics within 1 week

         11. Pregnancy

         12. RT-PCR performed &gt;7 days prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ammar Sarwar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ammar Sarwar</last_name>
    <phone>0423-530-2701</phone>
    <phone_ext>268</phone_ext>
    <email>asarwar@bidmc.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Expo Covid Isolation Center / Mayo Hospital Field Hospital</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ammar Sarwar, MD</last_name>
      <phone>0423-530-2701</phone>
      <phone_ext>268</phone_ext>
      <email>asarwar@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Hospital / King Edward Medical University</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ammar Sarwar, MD</last_name>
      <phone>0423-530-2701</phone>
      <phone_ext>268</phone_ext>
      <email>asarwar@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pakistan Kidney and Liver Institute</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ammar Sarwar, MD</last_name>
      <phone>0423-530-2701</phone>
      <phone_ext>268</phone_ext>
      <email>asarwar@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Services Hospital</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ammar Sarwar, MD</last_name>
      <phone>0423-530-2701</phone>
      <phone_ext>268</phone_ext>
      <email>asarwar@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Ammar Sarwar</investigator_full_name>
    <investigator_title>Assistant Professor, Harvard Medical School</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

